NASDAQ · RPRX
Royalty Pharma PLC
$58.83 -$0.19 (-0.32%) 1D After hoursKey Metrics
$26.16B
Market cap
31.62×
P/E · TTM
$2.44B
Revenue · TTM
$827.29M
Net income
EPS · TTM
$1.43
Dividend yield
—
Free cash flow
—
Beta · 1Y
0.24
EBITDA · TTM
—
Gross margin
—
Snapshot
Market cap$26.16B
Enterprise value$34.10B
Shares outstanding443.3M
52-wk range$34.08 – $59.72
Avg volume · 20D2.8M
Net cash
−$7.94B
Book value / share$17.19
IndustryPharmaceutical Preparations
ExchangeNASDAQ
About Royalty Pharma PLC
IPO dateJun 16, 2020
Employees100
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products.
Wolf Grade COMING SOON
—
The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.
Valuation
P/E31.62
P/S10.72
P/FCF—
EV/EBITDA—
EV/Sales13.97
Graham №$23.53
Profitability
Gross
—
Operating
55.7%
Net
33.9%
FCF
—
ROE / ROIC
8.2% · 7.4%
Financial Health
Current ratio2.66
Quick ratio—
Debt / equity0.90
Debt / EBITDA
—
Net cash
−$7.94B
Working capital$890.13M
Cash Flow · TTM
Operating CF
$2.61B
Capex
—
Free cash flow
—
Buybacks
$568.70M
Dividends paid
—
Shareholder yield
2.2%
Piotroski F-Score
4 / 9
Middling fundamentals · 4 of 9 signals passing
Altman Z-Score
2.2
Grey zone (1.81–2.99) · monitor
Graham Number vs Price
$23.53 vs $58.83
Trades 2.5× above classic defensive value — priced for growth
Fundamentals through 2026-03-31 · computed by TickerWolf from SEC filings